Please use this identifier to cite or link to this item:
Title: Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis (PSA) through 3 years: efficacy and safety results from a phase 3 trial
Authors: Hall, S.
Mease, P.
Kavanaugh, A.
Reimold, A.
Tahir, H.
Rech, J.
Pascale, P.
Delicha, E.
Pricop, L.
Mpofu, S.
Issue Date: 2017
Publisher: WILEY
Source: INTERNAL MEDICINE JOURNAL, 47, p. 37-38 (Art N° P90)
Abstract: Secukinumab, an anti–interleukin-17A monoclonal antibody, provided rapid and significant improvements in the key clinical domains of psoriatic arthritis (PsA) in the FUTURE 1 study (NCT01392326) with improvements sustained through 2 years. Here, we present efficacy and safety results through 3 years in the extension of the FUTURE 1 study.
Notes: [Hall, S.] Monash Univ, Melbourne, Vic, Australia. [Mease, P.] Swedish Med Ctr, Seattle, WA USA. [Mease, P.] Univ Washington, Seattle, WA 98195 USA. [Kavanaugh, A.] Univ Calif San Diego, Sch Med, La Jolla, CA USA. [Reimold, A.] Dallas VA Med Ctr, Dallas, TX USA. [Reimold, A.] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA. [Tahir, H.] Barts Hlth NHS Trust, London, England. [Rech, J.] Friedrich Alexander Univ Erlangen Narnberg Fau, Univ Klinikum Erlangen, Dept Internal Med Rheumatol & Immunol, Erlangen, Germany. [Geusens, P.] Univ Hasselt, Hasselt, Belgium. [Geusens, P.] Maastricht Univ Hosp, Maastricht, Netherlands. [Pascale, P.; Delicha, E.; Mpofu, S.] Novartis Pharma Ag, Basel, Switzerland. [Pricop, L.] Novartis Pharmaceut, E Hanover, NJ USA.
Document URI:
Link to publication:
ISSN: 1444-0903
e-ISSN: 1445-5994
ISI #: 000400304400113
Category: M
Type: Journal Contribution
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
acrabstracts_org_abstract_secukinumab_provides_sustained_imp.pdfPublished version65.7 kBAdobe PDFView/Open
Show full item record

Page view(s)

checked on May 19, 2022


checked on May 19, 2022

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.